You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 6,207,640

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,207,640

Title:	Treatment of partial growth hormone insensitivity syndrome
Abstract:	Methods for increasing the growth rate of a human patient having partial growth hormone insensitivity syndrome, but not Laron syndrome, are described. One such method comprises administering an effective dose of growth hormone, preferably growth hormone with a native human sequence, with or without an N-terminal methionine, to the patient. The patient is characterized as having a height of less than about -2 standard deviations below normal for age and sex, a serum level of high-affinity growth hormone binding protein that is at least 2 standard deviations below normal levels, a serum level of IGF-I that is below normal mean levels, and a serum level of growth hormone that is at least normal. In another such method, the same patient population is treated with an effective amount of IGF-I, given alone or in combination with an amount of growth hormone that is effective in combination with the IGF-I.
Inventor(s):	Attie; Kenneth M. (San Francisco, CA), Carlsson; Lena M. S. (Gothenburg, SE), Gesundheit; Neil (Los Altos, CA), Goddard; Audrey (San Francisco, CA)
Assignee:	Genentech, Inc. (South San Francisco, CA)
Application Number:	08/643,212
Patent Claims:	1. A method for increasing the growth rate of a human patient having partial growth hormone insensitivity syndrome, comprising administering an effective amount of growth hormone that increases the growth rate of the patient to said patient, whereby said patient has a height less than about -2 standard deviations below normal for age and sex, has a serum level of high-affinity growth hormone binding protein that is at least 2 standard deviations below normal levels, has a serum level of IGF-I that is below normal mean levels, and has a mean or maximum stimulated serum level of growth hormone that is at least normal, wherein the patient has a heterogeneous growth hormone receptor (GHR) gene defect, and does not have Laron syndrome. 2. The method according to claim 1 wherein the patient has an intracellular GHR gene defect. 3. The method according to claim 1 wherein the patient has an extracellular GHR gene defect. 4. A method for increasing the growth rate of a human patient with non-GH-deficient short stature but not Laron syndrome wherein said patient has a heterogeneous growth hormone receptor (GHR) gene defect, comprising detecting whether the patient has a height less than about -2 standard deviations below normal for age and sex, has a serum level of high-affinity growth hormone binding protein that is at least 2 standard deviations below normal levels, has a serum level of IGF-I that is below normal mean levels, and has a mean or maximum stimulated serum level of growth hormone that is at least normal, and, if so, administering an effective amount of growth hormone that increases the growth rate of the patient to said patient. 5. The method according to claim 4 wherein the patient has an intracellular GHR gene defect. 6. The method according to claim 4 wherein the patient has an extracellular GHR gene defect. 7. A method for increasing the growth rate of a human patient with non-GH-deficient short stature but not Laron syndrome wherein said patient has a heterogeneous growth hormone receptor (GHR) gene defect, comprising detecting whether the patient has a height less than about -2 standard deviations below normal for age and sex, has a serum level of high-affinity growth hormone binding protein that is at least 2 standard deviations below normal levels, has a serum level of IGF-I that is below normal levels, and has a mean or maximum stimulated serum level of growth hormone that is at least normal, and, if so, administering an effective amount of IGF-I to said patient. 8. The method according to claim 7 wherein the patient has an intracellular GHR gene defect. 9. The method according to claim 7 wherein the patient has an extracellular GHR gene defect. 10. A method for increasing the growth rate of a human patient having partial growth hormone insensitivity syndrome, comprising administering amounts of IGF-I and growth hormone that increases the growth rate of the patient to said patient which amounts are effective in combination, whereby said patient has a height less than about -2 standard deviations below normal for age and sex, has a serum level of high-affinity growth hormone binding protein that is at least 2 standard deviations below normal levels, has a serum level of IGF-1 that is below normal mean levels, and has a mean or maximum stimulated serum level of growth hormone that is at least normal, wherein the patient has a heterogeneous growth hormone receptor (GHR) gene defect and does not have Laron syndrome. 11. The method of claim 10 wherein the IGF-I and growth hormone are together administered by subcutaneous injections. 12. The method according to claim 10 wherein the patient has an intracellular GHR gene defect. 13. The method according to claim 10 wherein the patient has an extracellular GHR gene defect. 14. A method for increasing the growth rate of a human patient having partial growth hormone insensitivity syndrome whereby said patient has a heterogeneous GHR gene defect comprising administering an effective amount of growth hormone that increases the growth rate of the patient to said patient. 15. A method for increasing the growth rate of a human patient having partial growth hormone insensitivity syndrome whereby said patient has a heterogeneous gene defect comprising administering an effective amount of IGF-I to said patient. 16. The method according to claim 14 or 15 wherein the patient has an intracellular GHR gene defect. 17. The method according to claim 14 or 15 wherein the patient has an extracellular GHR gene defect. 18. A method for increasing the growth rate of a human patient with non-GH-deficient short stature but not Laron syndrome comprising detecting whether the patient has a heterogeneous GHR gene defect, and if so, administering an effective amount of growth hormone that increases the growth rate of the patient to said patient. 19. A method for increasing the growth rate of a human patient with non-GH-deficient short stature but not Laron syndrome comprising detecting whether the patient has a heterogeneous GHR gene defect, and if so, administering an effective amount of IGF-I to said patient. 20. The method according to claim 18 or 19 wherein the patient has an intracellular GHR gene defect. 21. The method according to claim 18 or 19 wherein the patient has an extracellular GHR gene defect.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.